Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is a member of the
tumor necrosis factor alpha family of
cytokines that preferentially induces apoptosis in transformed cells, making it a promising
cancer therapy. However, many
neoplasms are resistant to TRAIL-induced apoptosis by mechanisms that are poorly understood. We demonstrate that the expression of the
small heat shock protein alpha B-crystallin (but not other
heat shock proteins or apoptosis-regulating
proteins) correlates with TRAIL resistance in a panel of human
cancer cell lines. Stable expression of wild-type
alpha B-crystallin, but not a pseudophosphorylation mutant impaired in its assembly and chaperone function, protects
cancer cells from TRAIL-induced
caspase-3 activation and apoptosis in vitro. Furthermore, selective inhibition of
alpha B-crystallin expression by RNA interference sensitizes
cancer cells to TRAIL. In addition, wild-type
alpha B-crystallin promotes xenograft
tumor growth and inhibits TRAIL-induced apoptosis in vivo in nude mice, whereas a pseudophosphorylation
alpha B-crystallin mutant impaired in its anti-apoptotic function inhibits xenograft
tumor growth. Collectively, these findings indicate that
alpha B-crystallin is a novel regulator of TRAIL-induced apoptosis and
tumor growth. Moreover, these results demonstrate that targeted inhibition of
alpha B-crystallin promotes TRAIL-induced apoptosis, thereby suggesting a novel strategy to overcome TRAIL resistance in
cancer.